EcoDrugPlus

Receptor Tyrosine-Protein Kinase Erbb-3-Like

Ensembl ID : ENSPFOG00000005898
Gene Symbol: LOC103141120
3 Cross references
206 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSPFOG00000016673
Gene Symbol: RPTOR
1 Cross references
213 Possible Orthologues:

Renin

Ensembl ID : ENSPFOG00000012876
Gene Symbol: REN
1 Cross references
219 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSPFOG00000024271
Gene Symbol: RET
1 Cross references
205 Possible Orthologues:

Retinoic Acid Receptor Rxr-Beta-A-Like

Ensembl ID : ENSPFOG00000010127
Gene Symbol: LOC103150406
3 Cross references
211 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSPFOG00000006547
Gene Symbol: RARB
2 Cross references
392 Possible Orthologues:

Retinoic Acid Receptor Beta-Like

Ensembl ID : ENSPFOG00000004385
Gene Symbol: LOC103152855
2 Cross references
380 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSPFOG00000002278
Gene Symbol: RARG
1 Cross references
325 Possible Orthologues:

Retinoic Acid Receptor Gamma-A-Like

Ensembl ID : ENSPFOG00000002073
Gene Symbol: LOC103147616
3 Cross references
373 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSPFOG00000011556
Gene Symbol: RXRA
3 Cross references
225 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSPFOG00000012091
Gene Symbol: ROCK2A
1 Cross references
224 Possible Orthologues:

Rho-Associated, Coiled-Coil Containing Protein Kinase 2a

Ensembl ID : ENSPFOG00000012199
Gene Symbol: ROCK2A
1 Cross references
224 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).